We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A large majority of physician investigators and industry players are interested in electronic data capture (EDC) in clinical trials but uncertainty about the technology and its benefits has slowed its adoption, Clinipace Chief Scientific Officer Ronald Marks said.
Senior citizens who were administered Merck’s arthritis medication Vioxx faced the highest risk of heart attack during their first two weeks on the drug, according to a study published in the Canadian Medical Association Journal.
The suicide rate among older patients taking a class of antidepressants including Prozac, Paxil and Zoloft may be more likely to have intense suicidal thoughts or commit suicide during the earlier stages of treatment, according to data published in the current issue of the American Journal of Psychiatry.
Canada-based Lorus Therapeutics April 18 reported positive clinical study results for its antisense oligonucleotide drug, GTI-2040, in treating metastatic breast cancer.
An Eli Lilly osteoporosis drug cuts the risk of breast cancer in postmenopausal women, with fewer side effects than a widely used existing drug, according to a report issued April 17 by the National Cancer Institute.
After a four-year delay, researchers in India have received regulatory approval to restart the trial of a male contraceptive, reversible inhibition of sperm under guidance (RISUG) — a nonhormonal treatment that provides 10 or more years of protection after a 10- to 15-minute outpatient procedure.
Guidant has decided not to release current Xience V inventory and has voluntarily stopped enrolling new patients in one of its stent trials, because some of the products did not meet its manufacturing standards, Guidant announced March 29.
Wyeth’s recently expanded agreement with Expression Analysis should help the drugmaker more smoothly prepare electronic submissions of pharmacogenomic clinical data to the FDA.
Quebec-based medical device company ART Advanced Research Technologies has launched a Phase III clinical trial of its SoftScan breast imaging system at Toronto’s Princess Margaret Hospital.